International Stem Cell (OTC: ISCO) to sell LCT business for $25M
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
International Stem Cell Corporation agreed to sell 100% of the membership interests of its subsidiary Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. under a Membership Interest Purchase Agreement signed July 10, 2026. The aggregate purchase price is $25.0 million, subject to closing-date adjustments for net working capital, cash and indebtedness. Cash paid at closing will be reduced by an escrow totaling $2.6 million, comprised of a $100,000 adjustment escrow and a $2.5 million indemnity escrow.
The transaction includes a post-closing adjustment process: the purchaser delivers a closing statement within 90 days after closing, the seller may dispute it within 30 days, and unresolved items go to an independent financial firm. Closing is expected in the third fiscal quarter of 2026, subject to customary conditions and absence of blocking governmental actions.
Stockholders holding more than 50% of the seller’s voting power entered support agreements to approve the deal, grant irrevocable proxies, and restrict transfers, with written stockholder consent required within 24 hours of signing. The agreement imposes covenants on operating LCT in the ordinary course pre-closing, plus five-year post-closing non-solicitation, non-interference and non-compete restrictions, and provides for termination if not closed within 60 days, subject to a limited SEC-related extension.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Purchase Price: $25.0 million
Adjustment Escrow: $100,000
Indemnity Escrow: $2.5 million
+5 more
8 metrics
Purchase Price
$25.0 million
Aggregate purchase price for 100% of LCT membership interests
Adjustment Escrow
$100,000
Escrow fund to cover post-closing purchase price adjustments
Indemnity Escrow
$2.5 million
Escrow fund to secure indemnification obligations
Closing Statement Period
90 days
Time after closing for purchaser to deliver closing statement
Dispute Period
30 days
Time for seller to dispute the purchaser’s closing statement
Support Holders Voting Power
more than 50%
Voting power of stockholders signing support agreements
Non-compete Duration
five years
Post-closing duration of non-solicitation and non-compete covenants
Outside Date
60 days
Period after signing before either party may terminate if not closed, subject to extension
Key Terms
Membership Interest Purchase Agreement, indemnity escrow amount, post-closing adjustment process, non-solicitation covenant, +2 more
6 terms
Membership Interest Purchase Agreement regulatory
"entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”)"
A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.
indemnity escrow amount financial
"The escrow amount consists of a $100,000 adjustment escrow amount and a $2.5 million indemnity escrow amount."
post-closing adjustment process financial
"The Purchase Agreement provides for a post-closing adjustment process under which Purchaser is required"
non-solicitation covenant regulatory
"Seller is also subject to a non-solicitation covenant prohibiting solicitation of competing strategic transactions"
A non-solicitation covenant is a contract clause that stops one party from actively recruiting or doing business with the other party’s employees, customers or suppliers for a set time. Think of it as a temporary “do not lure” rule that protects relationships and team members after a deal or employment change. For investors, it reduces the risk that key staff or clients will be poached, helping protect revenue, integration plans and the value of the investment.
transition services agreement financial
"Purchaser and Seller also entered into a transition services agreement to be effective upon the closing"
A transition services agreement is a formal arrangement where one company continues to provide essential services—such as IT, human resources, or accounting—to another company after a business deal or change in ownership. It acts like a temporary bridge, ensuring smooth operations during a transition period. For investors, it provides clarity on how long support will last and helps assess potential costs and stability during the change.
irrevocable proxy regulatory
"Each support agreement also grants Purchaser an irrevocable proxy to vote the applicable stockholder’s shares"
An irrevocable proxy is a legal authorization in which a shareholder gives another person or entity the permanent right to vote their shares and cannot later take that voting permission back. It matters to investors because it locks who controls voting power on key issues—like board elections, mergers, or major policy changes—so it can change corporate control and influence the value or direction of an investment much like handing someone an unchangeable voting card.
FAQ
What transaction did ISCO announce involving Lifeline Cell Technology, LLC?
International Stem Cell Corporation agreed to sell 100% of the membership interests of Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. for an aggregate purchase price of $25.0 million, subject to customary closing and adjustment mechanisms.
What is the purchase price and escrow structure in ISCO’s LCT sale?
The aggregate purchase price is $25.0 million, adjusted for working capital, cash and debt. At closing, cash to the seller will be reduced by a $100,000 adjustment escrow and a $2.5 million indemnity escrow, totaling $2.6 million held in escrow.
When is the ISCO sale of Lifeline Cell Technology expected to close?
Closing of the Lifeline Cell Technology transaction is expected in the third fiscal quarter of 2026, subject to customary mutual closing conditions, including absence of prohibitive governmental orders or litigation challenging the deal.
What post-closing adjustment process applies to ISCO’s $25.0M LCT sale?
After closing, the purchaser must deliver a closing statement within 90 days. The seller has 30 days to dispute it, with unresolved items submitted to a nationally recognized financial services firm, and any final positive or negative adjustment settled between the parties or the adjustment escrow.
How have ISCO stockholders committed to support the LCT transaction?
Requisite holders with over 50% of ISCO’s voting power signed support agreements to vote in favor of the transaction, grant the purchaser irrevocable proxies if instructions are not delivered, and restrict transfers, with written stockholder consent required within 24 hours of signing.
What restrictive covenants affect ISCO after selling Lifeline Cell Technology?
For five years after closing, ISCO and its affiliates are subject to covenants prohibiting solicitation of specified LCT employees or consultants, interference with specified LCT business relationships, and engaging in LCT’s business in the covered geographic area, subject to a customary passive investment exception.